Indications for: ERVEBO
Prevention of disease due to Zaire ebolavirus.
Limitations of Use:
The duration of protection conferred by Ervebo is unknown. Does not protect against other species of Ebolavirus or Marburgvirus. Effectiveness of the vaccine when administered concurrently with antiviral medication, immuneglobulin, and/or blood or plasma transfusions is unknown.
Give by IM inj, preferably in deltoid region of the non-dominant arm. ≥18yrs: administer one (1mL) dose.
<18yrs: not established.
Allergy to rice protein.
Immunization may not protect all individuals. Have appropriate medical treatment and supervision available to manage allergic reactions. Immunocompromised. Possible transmission of vaccine virus. Pregnancy. Nursing mothers.
Ebola Zaire vaccine.
May test (+) results for anti-Ebola glycoprotein (GP) antibody and/or Ebola GP nucleic acid or antigens.
Inj site reactions (pain, swelling, redness), headache, feverishness, muscle pain, fatigue, joint pain, nausea, arthritis, rash, abnormal sweating.
Generic Drug Availability: